AOD 9604 5mg

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to a fragment of the C-terminus of human growth hormone (hGH), with a tyrosine residue added at the N-terminus. The molecule originated from research at Monash University in the 1990s investigating which parts of the hGH sequence drive its lipolytic effects independently of the insulin-resistance and IGF-1-elevating effects that the full hormone produces. The acronym 'AOD' stood for Anti-Obesity Drug in the original research program. This guide explains what AOD-9604 is, the published research context, and how its quality is independently verified.

AOD-9604 has the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe — 16 amino acids total. The two cysteine residues (positions 7 and 14) form an intramolecular disulfide bond that constrains the molecule into a small loop, mirroring the corresponding region of native human growth hormone (residues 177–191) with an N-terminal Tyr added for synthesis and labeling reasons. The molecular weight is approximately 1817 g/mol. It is supplied as a lyophilized white powder for laboratory reconstitution.

AOD-9604 is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

The Monash research program that produced AOD-9604 was specifically asking: can the lipolytic activity of growth hormone be uncoupled from its growth-promoting and metabolic side effects? Published animal-model work reported that AOD-9604 produced fat-loss endpoints in obese rodent models without elevating IGF-1, without inducing insulin resistance, and without the cell-proliferation signaling normally associated with the full hGH receptor. The proposed mechanism centers on activation of a beta-3 adrenergic-like pathway in adipocytes rather than via the canonical hGH receptor. The molecule entered human clinical trials in the early 2000s; researchers should evaluate the primary clinical and preclinical literature directly.

AOD-9604's quality verification is more demanding than for a typical linear 16-mer because the intramolecular disulfide bond must be formed in the correct topology. An incorrectly oxidized or reduced sample will have the same amino-acid content but different three-dimensional structure and different biological activity. Every batch of MHS Longevity AOD-9604 is submitted to an independent third-party laboratory before release:

Lyophilized AOD-9604 should be stored at -20°C or below for extended stability. Once reconstituted in bacteriostatic water, the solution is typically held at 2–8°C and used within the documented stability window. Disulfide-containing peptides are sensitive to reducing agents and to extreme pH — exposure to either can break the disulfide bridge and produce a structurally different molecule. Standard aseptic technique applies during reconstitution, and contact with reducing-agent contaminants (DTT, beta-mercaptoethanol residue on glassware) should be avoided.